O'Neill: Pharma Is Intrigued, Irritated But Respects The UK AMR Review
This article was originally published in Scrip
Executive Summary
Lord Jim O'Neill – ex-chair of Goldman Sachs Asset Management and the man appointed by UK Prime Minister David Cameron to launch and chair a review into the crisis of antibiotic resistance – spoke to Scrip at the recent BioInfect conference about what will happen when the Review of Antimicrobial Resistance (AMR) reaches its conclusion in summer 2016, pharma's reaction to the review so far, and how China is joining the game.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.